Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

C. Warren Olanow, Karl Kieburtz, Olivier Rascol, Werner Poewe, Anthony H. Schapira, Murat Emre, Helena Nissinen, Mika Leinonen, Fabrizio Stocchi

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing-off were performed at 3-month intervals for the 134- to 208-week duration of the study. The patients were divided into 4 dose groups based on nominal l-dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, 600 mg/day (n=77). Similar analyses were performed with respect to wearing-off and any motor complication. The times to onset and frequency of dyskinesia, wearing-off, or any motor complication were compared using the log-rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing-off increased in an l-dopa dose-dependent manner (P

Original languageEnglish
Pages (from-to)1064-1071
Number of pages8
JournalMovement Disorders
Volume28
Issue number8
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Dyskinesias
Levodopa
Parkinson Disease
Carbidopa
Dihydroxyphenylalanine
Proportional Hazards Models
Multivariate Analysis
Population

Keywords

  • Dyskinesia
  • Entacapone
  • Levodopa
  • Parkinson's disease
  • Wearing-off

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. / Warren Olanow, C.; Kieburtz, Karl; Rascol, Olivier; Poewe, Werner; Schapira, Anthony H.; Emre, Murat; Nissinen, Helena; Leinonen, Mika; Stocchi, Fabrizio.

In: Movement Disorders, Vol. 28, No. 8, 07.2013, p. 1064-1071.

Research output: Contribution to journalArticle

Warren Olanow, C, Kieburtz, K, Rascol, O, Poewe, W, Schapira, AH, Emre, M, Nissinen, H, Leinonen, M & Stocchi, F 2013, 'Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease', Movement Disorders, vol. 28, no. 8, pp. 1064-1071. https://doi.org/10.1002/mds.25364
Warren Olanow, C. ; Kieburtz, Karl ; Rascol, Olivier ; Poewe, Werner ; Schapira, Anthony H. ; Emre, Murat ; Nissinen, Helena ; Leinonen, Mika ; Stocchi, Fabrizio. / Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. In: Movement Disorders. 2013 ; Vol. 28, No. 8. pp. 1064-1071.
@article{ebbfdaa686b846f0ae60b55be2c2b633,
title = "Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease",
abstract = "The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing-off were performed at 3-month intervals for the 134- to 208-week duration of the study. The patients were divided into 4 dose groups based on nominal l-dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, 600 mg/day (n=77). Similar analyses were performed with respect to wearing-off and any motor complication. The times to onset and frequency of dyskinesia, wearing-off, or any motor complication were compared using the log-rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing-off increased in an l-dopa dose-dependent manner (P",
keywords = "Dyskinesia, Entacapone, Levodopa, Parkinson's disease, Wearing-off",
author = "{Warren Olanow}, C. and Karl Kieburtz and Olivier Rascol and Werner Poewe and Schapira, {Anthony H.} and Murat Emre and Helena Nissinen and Mika Leinonen and Fabrizio Stocchi",
year = "2013",
month = "7",
doi = "10.1002/mds.25364",
language = "English",
volume = "28",
pages = "1064--1071",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

AU - Warren Olanow, C.

AU - Kieburtz, Karl

AU - Rascol, Olivier

AU - Poewe, Werner

AU - Schapira, Anthony H.

AU - Emre, Murat

AU - Nissinen, Helena

AU - Leinonen, Mika

AU - Stocchi, Fabrizio

PY - 2013/7

Y1 - 2013/7

N2 - The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing-off were performed at 3-month intervals for the 134- to 208-week duration of the study. The patients were divided into 4 dose groups based on nominal l-dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, 600 mg/day (n=77). Similar analyses were performed with respect to wearing-off and any motor complication. The times to onset and frequency of dyskinesia, wearing-off, or any motor complication were compared using the log-rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing-off increased in an l-dopa dose-dependent manner (P

AB - The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) study compared the initiation of levodopa (l-dopa) therapy with l-dopa/carbidopa (LC) versus l-dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE-PD study population was investigated to determine the effect of l-dopa dose and other risk factors on the development of dyskinesia and wearing-off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing-off were performed at 3-month intervals for the 134- to 208-week duration of the study. The patients were divided into 4 dose groups based on nominal l-dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, 600 mg/day (n=77). Similar analyses were performed with respect to wearing-off and any motor complication. The times to onset and frequency of dyskinesia, wearing-off, or any motor complication were compared using the log-rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing-off increased in an l-dopa dose-dependent manner (P

KW - Dyskinesia

KW - Entacapone

KW - Levodopa

KW - Parkinson's disease

KW - Wearing-off

UR - http://www.scopus.com/inward/record.url?scp=84881558752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881558752&partnerID=8YFLogxK

U2 - 10.1002/mds.25364

DO - 10.1002/mds.25364

M3 - Article

C2 - 23630119

AN - SCOPUS:84881558752

VL - 28

SP - 1064

EP - 1071

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 8

ER -